Loading
For each treatment and each lasting effect, whether recovery is usual, partial or unlikely, how long it takes and in what proportion of people, with the source for every answer. The grid is mostly empty, because for most pairs nobody has published a recovery figure, and the page says how empty it is rather than hiding it.
Side effects are counted while a trial is running and reported as incidence. Almost nobody reports resolution: how many people got the function back, how long it took, and how many did not. That is the figure a person finishing treatment wants, and it is scattered through cohort studies, long-term follow-up papers and the recovery sentences buried in drug labels.
The matrix at /live/recovery/ gathers what exists: 37 treatments against 18 lasting effects, with every cell carrying whether recovery is usual, partial or unlikely, the timescale as the source states it, the proportion where a source gives one with the cohort it came from, and a verbatim fragment of the paper or label behind it. 104 of the 666 squares in the grid are filled, which is 15.6 per cent of it, and the page leads with that number because a matrix that looks complete and is half guessed is worse than no matrix. Seventeen more cells are the questions readers ask where the literature answers nothing, written out rather than left blank.
Some patterns only appear when the answers sit side by side. The nerve column is the fullest and the most consistent: platinum and taxane damage recovers in most people over months, and roughly a quarter to a third are left with something lasting. The hormone column is the one most often described as reversible and is not. Hearing after cisplatin is the clearest single answer on the page, and it is the most unwelcome: it does not come back, so prevention and early detection are the whole of the subject. The columns with almost nothing in them are also informative: lymphoedema, kidneys, bladder and bone have three to four sourced answers each across 37 treatments, which is a measure of how rarely recovery is followed up rather than a measure of how rarely it matters.
What the matrix is not: it is population data from trial and cohort populations that differ from any one reader, and a cell is an orientation for a conversation, not a prediction. The next page after this one is the survivorship planner, which gives the screening test and the interval for each late effect.
One row per treatment or class, one column per lasting effect, and in each cell an outlook, a timescale, a proportion with its cohort and a source. Cells are written only where a source states something about recovery; a blank is unknown, never none. The fill rate is computed from the data at build time, so the page cannot claim more coverage than it has.
Query for this technology: (TITLE:"What comes back after treatment, treatment by treatment" OR ABSTRACT:"What comes back after treatment, treatment by treatment") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about What comes back after treatment, treatment by treatment, not a curated reading list.
Shares Thinking and memory after cancer treatment: what is measurable, and what helps, Quality of life, Survivorship care and late-effects surveillance, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, late-effects.
Shares Thinking and memory after cancer treatment: what is measurable, and what helps, Quality of life, Survivorship care and late-effects surveillance, Late effects and survivorship toxicity and the tags rejuvenation, survivorship.
Shares The cumulative dose that decides whether it comes back, Heart function after anthracyclines, trastuzumab and chest radiotherapy, Trastuzumab, Late effects and survivorship toxicity and the tags rejuvenation, survivorship.
Shares Bone loss caused by cancer treatment, and what rebuilds it, Testicular germ cell tumours, Survivorship care and late-effects surveillance, Late effects and survivorship toxicity and the tags rejuvenation, survivorship.
Shares Hearing and tinnitus after platinum chemotherapy, Nerve damage from chemotherapy: what recovers, and what helps, Bone loss caused by cancer treatment, and what rebuilds it, Quality of life and the tags rejuvenation, survivorship.
Shares Testicular germ cell tumours, Quality of life, Survivorship care and late-effects surveillance, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, late-effects.
Shares Nerve damage from chemotherapy: what recovers, and what helps, Oxaliplatin, Paclitaxel / nab-paclitaxel, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Hearing and tinnitus after platinum chemotherapy, Late effects and survivorship toxicity, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship, late-effects.